Celea Therapeutics received $180 million in financing to develop deupirfenidone (LYT-100), an investigational therapy that the company says has the potential to serve as a new standard of care for people with idiopathic pulmonary fibrosis (IPF). The funding will support the planned launch of SURPASS-IPF (NCT07284602), a…
News
Problems in a cell death process called ferroptosis may contribute to the formation of scar tissue in the lungs in idiopathic pulmonary fibrosis (IPF), a study suggests. In ferroptosis, which is an iron-dependent process, reactive oxygen molecules damage cell membranes, leading to cell death. In the study, the researchers described…
GRI Bio‘s experimental oral therapy GRI-0621 (tazarotene) has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a disease with no known cause that’s marked by inflammation and fibrosis, or scarring, that damages the lungs. The developer…
Familial pulmonary fibrosis (FPF) makes up a notable portion of all cases of interstitial lung disease, disorders marked by scarring in the lungs, and tends to appear differently from non-familial versions of the disease, a large, multicenter study has found. While survival outcomes were similar between the two groups,…
Vaccines based on protein fragments unique to the scar-forming cells that drive idiopathic pulmonary fibrosis (IPF) significantly reduced lung scarring in both mouse models and human cell experiments, according to a study. While the vaccine approach showed promise in mice, advancing it to clinical trials will require patient selection…
A regulatory committee of the European Medicines Agency is urging approval of the oral therapy Jascayd (nerandomilast) in the European Union for treating adults with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), two forms of the respiratory disease. While the European Commission — which makes all final…
Two Phase 3 clinical trials testing Tyvaso (treprostinil) in people with idiopathic pulmonary fibrosis (IPF) both met their main goals, showing that the inhalation therapy significantly outperformed a placebo at slowing the decline in lung function among IPF patients. With these data in hand, Tyvaso’s developer, United…
Brainomix, a health software company, and drug developer Boehringer Ingelheim will advance testing of an artificial intelligence (AI)-based tool that may enable earlier diagnosis of progressive pulmonary fibrosis (PF). The two companies are collaborating to run studies of the Brainomix 360 e-Lung, a U.S. Food…
Insilico Medicine will soon launch an early clinical trial in China to test an inhaled version of its therapy candidate rentosertib in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF). This announcement follows the clearance of the company’s investigational new drug (IND) application by the Chinese Center for…
Enrollment has finished ahead of schedule in a Phase 2 clinical trial testing Calluna Pharma‘s experimental antibody therapy CAL101 in people with idiopathic pulmonary fibrosis (IPF). The Phase 2 study, dubbed AURORA (NCT06736990), was designed to enroll about 150 adults…
